Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib plus Anlotinib in EGFR-mutated Lung Adenocarcinoma with Brain Metastases
NCT06483672Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of furmonertinib, anlotinib in lung adenocarcinoma, brain metastases, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
furmonertinibanlotinib
03
Conditions
lung adenocarcinomabrain metastases
Beyond the preview
Go deeper on NCT06483672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483672.